Digital therapeutics and clinical pharmacology
- PMID: 32055575
- PMCID: PMC6989269
- DOI: 10.12793/tcp.2019.27.1.6
Digital therapeutics and clinical pharmacology
Abstract
Digital therapeutics (DTx) is a new subsection of digital health that is primarily driven by software and will be of great interest to clinical pharmacologists. In this article, an overview of DTx, including definition, position in the landscape of therapeutics, product categories, benefits, and challenges, is provided. Discussions from the point of view of clinical pharmacology are presented, as DTx should have exposure-response relationships. The principles of clinical pharmacology can be applied to DTx as they are comparable to pharmacotherapy. Clinical pharmacology has great potential in the development, application, and regulation of DTx.
Keywords: Clinical pharmacology; Digital therapeutics; Healthcare.
Copyright © 2019 Jae-Yong Chung.
Conflict of interest statement
Conflict of interest: - Authors: The author has no conflict of interest to declare. - Reviewers: Nothing to declare - Editors: Nothing to declare
Figures
References
-
- FDA permits marketing of mobile medical application for substance use disorder. [Accessed 12 February 2019]. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576087.htm.
-
- Digital Therapeutics Alliance. [Accessed 10 January 2019]. https://www.dtxalliance.org/
-
- Digital therapeutics. [Accessed 10 January 2019]. https://en.wikipedia.org/wiki/Digital_therapeutics.
-
- Digital Therapeutics: Combining Technology and Evidence-based Medicine to Transform Personalized Patient Care. [Accessed 10 January 2019]. https://www.dtxalliance.org/wp-content/uploads/2018/09/DTA-Report_DTx-In....
Publication types
LinkOut - more resources
Full Text Sources